Pre-made Ganitumab benchmark antibody ( Whole mAb, anti-IGF1R therapeutic antibody, Anti-IGFR/CD221/IGFIR/JTK13 Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-231

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-231 Category Tag

Product Details

Pre-Made Ganitumab biosimilar, Whole mAb, Anti-IGF1R Antibody: Anti-IGFR/CD221/IGFIR/JTK13 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Ganitumab a human monoclonal antibody against type 1 insulin-like growth factor receptor (IGF1R), designed for the treatment of cancers.

Products Name (INN Index)

Pre-Made Ganitumab biosimilar, Whole mAb, Anti-IGF1R Antibody: Anti-IGFR/CD221/IGFIR/JTK13 therapeutic antibody

INN Name

Ganitumab

Target

IGF1R

Format

Whole mAb

Derivation

Human

Species Reactivity

Human

CH1 Isotype

IgG1

VD LC

Kappa

Highest_Clin_Trial (Jan '20)

Phase-III

Est. Status

Active

100% SI Structure

None

99% SI Structure

None

95-98% SI Structure

None

Year Proposed

2010

Companies

Amgen,Millennium,NantWorks,National Cancer Institute (USA),Novartis,Takeda,Takeda Oncology,UCLAs Jonsson Comprehensive Cancer Center

Conditions Approved

NA

Conditions Active

Ewing's sarcoma,Solid tumours,Rhabdomyosarcoma

Conditions Discontinued

Breast cancer,Colorectal cancer,Sarcoma,Small cell lung cancer,Non-small cell lung cancer,Pancreatic cancer,Prostate cancer

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

IGF1R

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide